Nurtec ODT is indicated in adults for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

Calcitonin gene-related peptide (CGRP) is a key mediator in migraine[1]

CGRP IS A PAIN-SIGNALING NEUROPEPTIDE RELEASED BY THE TRIGEMINAL NERVE[1,2]



For illustrative purposes only.

CGRP LEVELS ARE ELEVATED DURING A MIGRAINE ATTACK[1,3,4]

Activation of CGRP receptors may lead to[2,5,6]:

- **VASODILATION**
- **INFLAMMATION**
- **PAIN SIGNALING**

MIGRAINE PATHOPHYSIOLOGY IS MULTIFACTORIAL

It is now understood that the disorder involves a complex interplay between three distinct systems: the nervous system, specifically the trigeminal nerve; the vascular system, including intracranial meningeal arteries; and inflammatory pathways, involving satellite glial cells and mast cells.[2,5,7]

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Please see additional Important Safety Information on the next page and full Prescribing Information.

Nurtec ODT (rimegepant) blocks CGRP receptors[8]

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

RIMEGEPANT INHIBITS CGRP FROM BINDING TO THE CGRP RECEPTOR[8]



REDUCING CGRP BINDING RESULTS IN THE INHIBITION OF[2,5,6]:

- VASODILATION
- INFLAMMATION
- PAIN SIGNALING

The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.[8]

Nurtec ODT does not cause vasoconstriction.[2,9,10]

The Nurtec ODT mechanism of action has not been associated with medication overuse headache.[11,*]

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

*The safety of using more than 18 doses in a 30-day period has not been established.[8]

Please see additional Important Safety Information on the next page and full Prescribing Information.

One Medication—Two Indications[8]

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

NURTEC ODT IS INDICATED IN ADULTS FOR:

- **The acute treatment of migraine with or without aura**
- **The preventive treatment of episodic migraine**

ONE DISSOLVABLE 75 MG TABLET[8]

ACUTE TREATMENT[8]

Prescribe 8 or 16 tablets.

SIG: Take one Nurtec ODT 75 mg, **as needed**, for the acute treatment of migraine with or without aura.[8]

PREVENTIVE TREATMENT[8]

Prescribe 16 tablets.

SIG: Take one Nurtec ODT 75 mg **every other day** for the preventive treatment of episodic migraine.[8]

- No water needed; can be taken with or without food[8]
- Dissolves rapidly within seconds[12]
- The ODT formulation may be helpful for patients who experience nausea and vomiting[13]
- T_{max} of 1.5 hours and an elimination half-life of ~11 hours[8]
- The maximum dose in a 24-hour period is 75 mg[8]
  - The safety of using more than 18 doses in a 30-day period has not been established[8]

ODT=orally disintegrating tablet.

GENERALLY WELL TOLERATED FOR ACUTE AND PREVENTIVE TREATMENT

- The most common adverse event (AE) in the acute study was nausea (Nurtec ODT 2%; placebo 0.4%)[8]
- The most common AEs in the preventive study were nausea (Nurtec ODT 2.7%; placebo 0.8%) and abdominal pain/dyspepsia (Nurtec ODT 2.4%; placebo 0.8%)[8]
- Not contraindicated in patients with stable cardiovascular disease or risk factors[8]
- Nurtec ODT was not associated with serious adverse events, and <3% of patients discontinued due to AEs[13-16,*]

*A serious adverse event was defined as any event that meets any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a subject who received rimegepant, and others.[17]

Please see full Prescribing Information.

SELECT IMPORTANT SAFETY INFORMATION

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

References: 1. Ho TW, Edvinsson L, Goadsby PJ . *Nat Rev Neurol.* 2010;6(10):573-582. **2.** Edvinsson L, Haanes KA, Warfvinge K, Krause DN. *Nat Rev Neurol.* 2018;14:338-350. **3.** Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. *Pain.* 2000;86:133-138. **4.** Lassen LH, Haderslev PA, Jacobsen VB, et al. *Cephalalgia.* 2002;22:54-61. **5.** Fabbretti E, D'Arco M, Fabbro A, et al. *J Neurosci.* 2006;26:6163-6171. **6.** Edvinsson L. *J Intern Med.* 2022;292:575-586. **7.** Guan LC, Dong X, Green DP. *Mol Pain.* 2023;19:17448069231181358. doi: 10.1177/17448069231181358. **8.** Nurtec ODT. Package insert. Pfizer Inc. 2024. **9.** Conway CM, Dubowchik G, Coric V. Presented at: the 60th Annual Meeting of the American Headache Society; June 28-July 1, 2018; San Francisco, CA. *Headache.* 2018;58(8):1295. **10.** True D, Mullin K, Croop R. *Pain Ther.* 2024. doi: 10.1007/s40122-024-00626-1 Online ahead of print. **11.** Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. *Headache.* 2021;61:1021-1039. doi: 10.1111/head.14153 **12.** Abay FB, Ugurlu T. *J Pharm Drug Devel.* 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303 **13.** Croop R, Goadsby PJ, Stock DA, et al. *Lancet.* 2019;394(10200):737-745. doi:10.1016/S0140-6736(19)31606-X **14.** Croop R, Lipton RB, Kudrow D, et al. *Lancet.* 2020;397(10268): 51-60. doi: 10.1016/S0140-6736(20)32544-7 **15.** Croop R, Berman G, Kudrow D, et al. *Cephalalgia.* 2024;44(4):1-11. **16.** Lipton RB, Kudrow D, Smith T, et al. Presented at the American Headache Society's Annual Scientific Meeting, June 9-12, 2022. Denver, CO and virtual. **17.** Study BHV3000-303 Clinical Protocol. ClinicalTrials.Gov. https://clinicaltrials.gov/ProvidedDocs/57/NCT03461757/Prot_000.pdf. Published July 23, 2018. Accessed September 4, 2024.